STATEN ISLAND, N.Y., March 9, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for ...
A day before a scheduled March 19 federal court hearing over disputed assessment fees issued by the Horseracing Integrity and ...
Acurx is launching a ground-breaking clinical trial with ibezapolstat in patients with multiply-recurrent CDI (rCDI) that has the potential to shift the paradigm of treatment and prevention of rCDI ...
Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx previously announced that it had received positive regulatory guidance from the ...
Your CDI Program Isn’t the Problem If clinical denial rates are still climbing despite your Clinical Documentation ...
Paulick Report on MSN
Churchill, HISA Reach Agreement On Fees; No Details Made Public
Churchill Downs Inc. (CDI) and the Horseracing Integrity and Safety Authority (HISA) have reached an agreement regarding the ...
Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive global license agreement with Valneva SE (Nasdaq: ...
Q4 2025 Management View David Luci, President and CEO, highlighted a series of corporate milestones, including the receipt of $1.4 million in gross proceeds from the execution of Series F Warrants in ...
The CUNY Dance Initiative (CDI), an expansive program providing New York City choreographers and dance companies with ...
Churchill Downs and racing regulator HISA reached an agreement over millions in unpaid fees, ensuring the Kentucky Derby is ...
The second formula — which was approved by the Federal Trade Commission, HISA's oversight agency — is a purse-weighted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results